Special Advertising

Pivotal Therapeutics Inc. (PVO:CNX) Stock Quote

Detailed Quote for Pivotal Therapeutics Inc. (PVO:CNX)
$ 0.10   0.01 (+11.11%) Volume: 24k 1:44 PM EST Jan 30, 2015
Today 5d 1m 3m 1y more
Last Price
0.10
Change $
0.01
Change %
11.11%
Tick
  
Bid
0.09
Bid Size
1,000
Ask
0.10
Ask Size
149,000
Open
0.09
High
0.10
Low
0.08
Prev Close
0.09
Last Trade
01/30/15
Volume
24k
52 Wk Hi
0.24
52 Wk Low
0.02
Market Cap
9.35m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
93,469,236
EPS (TTM)
-0.07
PE Ratio
N/A
Exchange
CSE
News and Media for Pivotal Therapeutics Inc. (PVO:CNX)
Sector News | Topic News
News for Pivotal Therapeutics Inc. (PVO:CNX)
Tue, Jan 27, 2015
1:23 PM Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100 - Canada Newswire
1:23 PM Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100 - PR Newswire
Thu, Jan 22, 2015
3:38 PM Pivotal Therapeutics: Year in Review and CEO Update - Canada Newswire
3:38 PM Pivotal Therapeutics: Year in Review and CEO Update - PR Newswire
Mon, Jan 05, 2015
5:10 PM Pivotal Therapeutics announces payment of interest on outstanding convertible notes - Canada Newswire
5:10 PM Pivotal Therapeutics announces payment of interest on outstanding convertible notes - PR Newswire
Wed, Dec 17, 2014
7:32 AM VASCAZEN\u00AE POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA - PR Newswire
7:30 AM VASCAZEN\u00AE POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA - PR Newswire
7:30 AM VASCAZEN\u00AE POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA - Canada Newswire
Fri, Nov 28, 2014
5:22 PM Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results - Canada Newswire
5:22 PM Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results - PR Newswire
Fri, Nov 14, 2014
3:15 PM Pivotal Therapeutics Announces Senior Management Change - Canada Newswire
3:15 PM Pivotal Therapeutics Announces Senior Management Change - PR Newswire
Wed, Oct 08, 2014
3:00 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - PR Newswire
12:44 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - Canada Newswire
12:44 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - PR Newswire
Tue, Oct 07, 2014
7:00 AM Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN\u00AE and Statin Therapy - PR Newswire
7:00 AM Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN\u00AE and Statin Therapy - Canada Newswire
7:00 AM Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN\u00AE and Statin Therapy - PR Newswire
Fri, Oct 03, 2014
2:37 PM Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes - Canada Newswire
More News for PVO:CNX >>

Tags for Pivotal Therapeutics Inc.

Research stocks or mutual funds related to Pivotal Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to PVO:CNX. The keywords below have been associated to PVO:CNX by either user submission or electronic means.